Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Frontiers in OncologyOpen Access

Correlation study of tumor-infiltrating lymphocytes combined with residual cancer burden and prognosis in breast cancer patients receiving neoadjuvant chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZHZexin HouXAXin AnGMGloria Meng

Discussion

Loading...

Member takes

Overview

Correlation study shows RCB-TILs significantly predict disease-free survival in breast cancer patients post-neoadjuvant chemotherapy.

Key Points

  • RCB-TILs (+) are associated with improved disease-free survival in breast cancer patients following neoadjuvant chemotherapy.
  • The analysis included 242 breast cancer patients, revealing a hazard ratio of 0.225 for recurrence among RCB-TILs (+) patients.
  • Multivariate analysis confirmed RCB-TILs as an independent predictor of recurrence across hormone receptor-positive and triple-negative breast cancers.
  • Using RCB-TILs may enhance prognostic accuracy in breast cancer, indicating a need for tailored treatment strategies.

Cite This Study

Hou et al. (2025) studied this question.

synapsesocial.com/papers/68d44c4d31b076d99fa55d89https://doi.org/10.3389/fonc.2025.1538326
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer2024
  2. 2Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer2024
  3. 3Abstract PS2-10-04: Tumor-infiltrating lymphocytes - a promising predictive and prognostic biomarker for optimizing neoadjuvant treatment response: a single-institution retrospective analysis2026
  4. 4Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer2024 · 1 citations
  5. 5PS2-05-16: Prognostic value of TILs variation in breast cancer undergoing neoadjuvant chemotherapy2026